Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-64558 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-c-Met (Ser985) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Phospho-c-Met (Ser985) Polyclonal Antibody detects endogenous levels of c-Met only when phosphorylated at Ser985.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation.
Virzì AR, Gentile A, Benvenuti S, Comoglio PM
Proceedings of the National Academy of Sciences of the United States of America 2018 Oct 2;115(40):10058-10063
Proceedings of the National Academy of Sciences of the United States of America 2018 Oct 2;115(40):10058-10063
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of c-Met in serum treated 293 whole cell lysates using a Phospho-c-Met (Ser985) Polyclonal Antibody (Product # PA5-64558).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3. Mechanistic explanation of the feedback loop between BRAF and MET. Biochemical analysis of phosphoproteins from L1.13 cell lysates treated with different inhibitors and analyzed by immunoblotting. ( A ) Treatment with increasing concentrations of TAK-632. The BRAF specific inhibitor induces dose-response MET phosphorylation, whereas P-ERK coherently decreases. ( B ) Time-course treatment of L1.13 cells with AZD-6244 (500 nM). MEK inhibition recapitulates BRAF inhibition and is followed by MET phosphorylation. ( C ) Treatment of L1.13 cells for 30 min with the Ser/Thr phosphatases inhibitor sodium fluoride, NaF (25 mM), alone or in combination with AZD-6244 (500 nM). NaF abrogates AZD-6244-induced MET phosphorylation, indicating the involvement of a Ser/Thr phosphatase in the phenomenon. ( D and E ) Treatment of L1.13 with AZD-6244 500 nM for 30 min is followed by concomitant activating dephosphorylation of PP2A phosphatase, MET Ser985 dephosphorylation (immunoprecipitates in E ). ( F and G ) Silencing of PP2A Ser/Thr phosphatase by two siRNAs (#58 and #59) targeting different sites. Scrambled siRNA was used as control (CTRL). Cells were treated with AZD-6244 (500 nM) for 30 min, and lysates were analyzed as earlier. DMSO was used as control vehicle. PP2A silencing prevents AZD-6244-induced MET Tyr1234-1235 phosphorylation ( F ) and abrogates dephosphorylation of MET Ser985 (immunoprecipitates in G ). Antibodies used for Western blots analysis: P-Y/S-MET, MET